While the major impact of hypomagnesemia on cardiovascular outcomes and T2DM has been known, recent evidence suggests that SGLT2 inhibitors may normalize Mg2+ levels.
Read More »Canagliflozin’s Efficacy and Safety For Delaying and Possibly Preventing ESKD
Kidney failure is an enormous concern for people with T2D and DKD. This analysis confirms canagliflozin can slow its progression and have an impact on patients regardless of their level of kidney function.
Read More »Head-to-Head Comparison: Oral Semaglutide vs. Empagliflozin
The first oral glucagon-like peptide receptor agonist recently gained FDA approval, but how does it compare to oral agents already on the market?
Read More »Fracture Risk and Sodium-Glucose Transport Inhibitors
Did the FDA make a mistake by labeling SGLT2 inhibitors as a fracture risk?
Read More »SGLT Inhibitors as Adjunct Therapy with Insulin
In regards to pharmacotherapy, patients with type 1 diabetes end up solely relying on insulin therapy for their diabetes management: what if there is an add on option?
Read More »New Approved Complete Diabetes Regimen in One Tablet
Diabetes has never been simpler to control with this once daily pill.
Read More »First Major Breakthrough In 20 Years For The Treatment of Diabetic Kidney Disease and Heart Failure
FDA has approved a new treatment for diabetic kidney disease, which affects one in three patients with type 2 diabetes.
Read More »New Diabetes Medications Have Reduced Heart Failure Risk by 34 Percent
Study examines SGLT-2 inhibitors versus DPP-4 in reducing cardiovascular events.
Read More »FDA Rejects Dapagliflozin for Type 1 Diabetes
The FDA rejected dapagliflozin as a treatment for type 1 diabetes although it was recently approved in Europe and Japan.
Read More »Renal Outcomes After Canagliflozin Use in Patients with Type 2 Diabetes
Diabetes mellitus is the leading cause of end-stage renal disease (ESRD) worldwide.
Read More »